| Previous Close | 35.51 |
| Open | 35.51 |
| Bid | 35.46 x 3100 |
| Ask | 35.47 x 1000 |
| Day's Range | 35.37 - 35.65 |
| 52 Week Range | 29.83 - 36.21 |
| Volume | 3,127,079 |
| Avg. Volume | 16,973,851 |
| Market Cap | 211.07B |
| Beta | 1.06 |
| PE Ratio (TTM) | 25.96 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.61%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- American City Business Journals•22 hours ago
Pfizer helps pump $103M into startup to develop new cancer therapies
A local startup has been spun-out of Pfizer to develop clinical-stage experimental therapies. Nascent medicine company SpringWorks Therapeutics completed a $103 million series A round led by the New York-based pharma giant with the help of Bain Capital, OrbiMed and LifeArc (formerly known as MRC Technology). Pfizer (PFE) granted SpringWorks the rights to help develop four drugs or therapies that treat various conditions, including post-traumatic stress disorder and cancer.
- Bloomberg•yesterday
Pfizer Channels Its Inner Biotech
Four pipeline castoffs should fetch a higher valuation standing alone.
- Financial Times•yesterday
[$$] Pfizer tests new way of putting more drugs on trial
Pfizer has backed a new drug development company with the task of shepherding four of its experimental medicines through clinical trials, in an unusual deal designed to prevent promising products from ...
